Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
7 hedge funds and large institutions have $522K invested in Cellular Biomedicine Group, Inc. in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$409K |
| 2 |
Morgan Stanley
New York
|
+$64.5K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$16.3K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$10.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.46K |
Top Sellers
CBMG Hedge Fund Activity: Q3 2014 in Review
7 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q3 2014, worth a combined $522K.
Buyers outnumbered sellers: 7 funds opened new CBMG positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $409K.
- 7 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $522K of Cellular Biomedicine Group, Inc. stock for Q3 2014.
- 7 funds opened new Cellular Biomedicine Group, Inc. positions in Q3 2014 and 0 closed out, a net change of +7 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q3 2014 was Goldman Sachs, an estimated $409K added.
Based on aggregated 13F filings for Q3 2014.